EU GMP audit delay for Ambernath facility
EU authority cited low manpower as reason for inability to provide immediate audit dates. Expected 3-4 months delay (Q1 FY27) could postpone regulated market traction for CDMO business.
SUPRIYA / Q3-FY26 / risks
Keep the risk register visible.
Supriya Lifescience · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
ATS-8 customer price acceptance uncertainty
Market not yet accepting $105+ import price levels. Large users targeted for export are already approved; domestic market ambiguity persists. No firm annual contracts in place—only volume commitments being signed.
DSM project revenue timing risk
Pharma validation completed in January; meaningful contribution pushed to H2 FY27 vs earlier H1 expectations. Protein project R&D completion in 3-4 months adds further timeline uncertainty.
Isambe greenfield timeline
Environmental clearance took 2.5 years to obtain. Blueprint finalization stage; 9-12 months before any meaningful disclosure possible. Long gestation period for new capacity.